NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share insights on this topic.
- Others, such as Mark Agulnik, MD, Mrinal M. Zuckerman, MD, and Daniel Lefler, MD, also contribute to the discussion.
- Additional experts like Naval G. Daver, MD, Jessica Altman, MD, and Amir T. Roboz, MD, provide further perspectives.
Next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
Author's summary: Next-generation sequencing enhances biomarker testing.
More News
- Switzerland To Change Designs
- V Levels must build on the best of BTECs, not erase them
- Protecting Your Loved Ones: Estate Law Attorneys in Woodbury, NJ You Can Trust | NorthPennNow
- GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate | PharmExec
- Navy Loses Two Aircraft From USS Nimitz Aircraft Carrier Within 30 Minutes
- NGS Streamlines Biomarker Testing in Solid Tumors | Oncology Nursing News
- State begins distributing disaster aid to residents of Western Alaska, federal aid also approved
- Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project Front - FNArena.com
- One UI 8 update rolls out for Samsung Galaxy M55s and F55
- Man Utd Failed With £50 Million Mbeumo Alternative